alexa Emerging antiangiogenic treatments for gliomas - efficacy and safety issues.
Biochemistry

Biochemistry

Biochemistry & Physiology: Open Access

Author(s): Dietrich J, Norden AD, Wen PY

Abstract Share this page

Abstract PURPOSE OF REVIEW: To review the rationale and recent experience of angiogenesis inhibitors in malignant gliomas and to highlight both the promise and potential complications of these agents. RECENT FINDINGS: Several new agents targeting angiogenesis in malignant gliomas have become available and have been increasingly used to complement conventional chemotherapy. Specifically, bevacizumab, often in combination with irinotecan, has demonstrated favorable results in achieving significant radiographic responses and in prolonging progression-free survival in patients with recurrent malignant glioma. SUMMARY: Antiangiogenic drugs have been shown to have promising activity in recurrent malignant gliomas. Investigation of novel antiangiogenic compounds and future clinical trials will determine whether these drugs have a role in first-line therapy. This article reviews the rationale for targeting angiogenesis in malignant brain tumors and summarizes the results of recent clinical trials. In addition, this review will outline potential toxicities associated with angiogenesis inhibition in an attempt to provide practical guidance to physicians treating patients with malignant gliomas. This article was published in Curr Opin Neurol and referenced in Biochemistry & Physiology: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords